Abbisko Cayman Limited: Irpagratinib Combination Therapy Begins Phase II Dosing for Advanced HCC

Key Highlights of the Announcement

• First Patient Dosed in Phase II Study: Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has dosed the first patient in a Phase II clinical trial of irpagratinib (ABSK-011), a highly selective, oral small-molecule FGFR4 inhibitor, combined with standard of care (toripalimab and bevacizumab biosimilar) for first-line treatment of advanced or unresectable hepatocellular carcinoma (HCC) [[1]].
• Targeted Therapy for High-Risk HCC Subgroup: The trial targets patients with FGF19-overexpressing HCC, a molecular subtype associated with poorer outcomes under current standard treatments. About 30% of HCC patients worldwide exhibit FGF19 overexpression, representing a significant unmet medical need [[2]].
• Strong Preliminary Efficacy: Previous Phase II data presented at the 2025 ESMO GI Congress showed that irpagratinib in combination with atezolizumab achieved an objective response rate (ORR) exceeding 50% and median progression-free survival (mPFS) of more than 7 months in FGF19-overexpressing HCC patients, including those previously treated with immune checkpoint inhibitors. The safety profile was manageable with no new safety signals [[2],[3]].
• Innovative Mechanism: Irpagratinib targets the FGFR4/FGF19 pathway, which is implicated in immune evasion and metastasis in HCC. Persistent activation of this pathway upregulates PD-L1 expression, reducing the effectiveness of immunotherapy combinations. Combining an FGFR4 inhibitor with standard immunotherapy and anti-angiogenic therapy could address this resistance mechanism and enhance antitumor activity [[2]].

Potential Implications for Shareholders

• Market Opportunity: There are currently no approved therapies targeting the FGFR4/FGF19 pathway for HCC. The successful development and approval of irpagratinib could position Abbisko Cayman Limited as a leader in precision oncology for liver cancer, opening a substantial new market segment [[2]].
• Clinical Milestone: Initiation of patient dosing in Phase II marks a critical milestone in drug development and is a positive signal for Abbisko’s pipeline progress. If clinical results continue to be favorable, this could significantly impact Abbisko’s valuation and investor sentiment.
• Risk Disclosure: The Company cautions that there is no guarantee irpagratinib (ABSK-011) will ultimately be successfully marketed. Investors should exercise caution, as clinical development carries inherent risks and uncertainties [[1]].
• Ongoing Research: Abbisko is actively exploring further combinations of irpagratinib with other standard-of-care therapies. As more clinical data accumulates, the potential for broader indications and market reach may increase [[2]].

Detailed Clinical and Scientific Background

Primary liver cancer is the third leading cause of cancer-related mortality globally, with HCC accounting for 75%-85% of cases. While targeted immunotherapy (immune checkpoint inhibitors combined with anti-angiogenic therapy) is the standard first-line treatment for advanced HCC, outcomes differ based on molecular subtype. Patients with FGF19 overexpression have significantly shorter mPFS and lower ORR compared to those with low FGF19 expression (mPFS: 6.1 vs. 11.4 months; ORR: 33.3% vs. 45.2%). This is thought to be due to aberrant activation of the FGFR4/FGF19 pathway, which drives immune evasion and metastasis [[2]].

Irpagratinib, developed by Abbisko Therapeutics, precisely targets this pathway. Previous studies have shown promising efficacy, particularly in the high-risk FGF19-overexpressing subgroup. The new Phase II trial will systematically assess the safety, tolerability, and preliminary efficacy of irpagratinib combined with toripalimab and bevacizumab biosimilar as a first-line option for these patients [[2]].

Abbisko Therapeutics is based in Shanghai and focuses on the discovery and development of innovative medicines for unmet medical needs in China and globally. Founded by experienced researchers and managers from top multinational pharmaceutical companies, Abbisko has built a pipeline centered on precision oncology and immuno-oncology [[3]].

Board and Corporate Information

• Chairman: Dr. Xu Yao-Chang
• Executive Directors: Dr. Xu Yao-Chang, Dr. Yu Hongping, Dr. Ji Jing
• Independent Non-Executive Directors: Dr. Sun Piaoyang, Mr. Sun Hongbin, Ms. Chui Hoi Yam

For further corporate and pipeline details, please visit www.abbisko.com.

Disclaimer

This article contains forward-looking statements based on information available as of the date of publication. Actual future results may differ materially due to a variety of risks and uncertainties. Abbisko Cayman Limited and its subsidiaries do not undertake any obligation to update or revise forward-looking statements, except as required by law. Investors should read this article in full and exercise caution when dealing in the shares of the Company, as clinical trial outcomes and regulatory decisions may significantly impact the Company’s share value.

View ABBISKO-B Historical chart here